PECULIARITIES OF PHARMACEUTICAL CARE DURING THE COVID-19 PANDEMIC
DOI:
https://doi.org/10.11603/2312-0967.2022.1.13055Keywords:
COVID-19 pandemic, pharmaceutical care, symptomatic treatment, cold symptoms, drugs (medicines)Abstract
The aim of the work. To analyze the use of drugs for the symptomatic treatment of colds (within the framework of pharmaceutical care) during COVID-19 pandemic.
Materials and Methods. A population survey of 56 people aged 18–87 and of 36 pharmacists aged 20–38 years was conducted. Questionnaires were compiled for the survey, which included passport data and questions on the use of drugs for cold symptoms during COVID-19 pandemic.
Results and Discussion. Analysis of population questionnaires on the choice of drugs demonstrated prescription preferences by physicians (59 %) and pharmacists (23 %). Pharmacists indicated that in choosing the symptomatic pharmacotherapy of cold symptoms among the most important factors there were personal experience and research data which were estimated at 4.3 and 4.2 score points, respectively (on a 5-point scale). As an antipyretic drug, respondents preferred paracetamol and other drugs based on it, which corresponds to the current pharmacist protocols, as well as to recommendations of drugs for sore throat, cough and rhinitis.
Conclusions. In order to optimize the pharmaceutical care of patients with colds it is advisable to supplement current pharmacist protocols with a separate protocol for the treatment of COVID-19, taking into account threatening symptoms and recommendations for prevention, including vaccination.
References
Andreichyn MA, Nychyk NA, Zavidniuk NH, Yosyk YI, Ishchuk IS, Ivakhiv OL. [COVID-19: epidemiology, clinical manifestations, diagnosis, treatment and prevention]. Infektsiini khvoroby. 2020;2: 41-55. Available from: http://nbuv.gov.ua/UJRN/InfKhvor_2020_2_8. Ukrainian.
Kovalenko VM, Nesukay EG, Korniyenko TM, Titova NS. [The COVID-19 pandemic and cardiovascular diseases]. Ukr J Card. 2020;27(2): 10-17. doi:10.31928/1608-635X-2020.2.1017.
Malyi VP, Asoian IM, Sai IV, Andrusovych IV. [Pathogenesis of coronavirus infection COVID-19]. Infektsiini khvoroby. 2020;3:73-83. Available from: http://nbuv.gov.ua/UJRN/InfKhvor_2020_3_12. Ukrainian.
Guan WJ, Ni Z, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. – 2020. – Vol. 18, N 382. – P. 1708-1720.
Ministry of Health of Ukraine. [Protocol of medical care provision for the treatment of coronavirus disease (Covid-19)] [Internet]. Kyiv: Ministry of Health of Ukraine; [2021; cited 2022 May 12]. Available from: https://moz.gov.ua/uploads/5/29766-dn_638_06_04_2021_dod.pdf. Ukrainian.
Pharmacist protocols when giving medicines for patients. [Internet]. Kyiv: State Expert Centre of the Ministry of Health of Ukraine; [2022; cited 2022 May 12]. Available from: https://www.dec.gov.ua/wp-content/uploads/2022/01/2022_7_pf.pdf. Ukrainian.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
